Tim van Hauwermeiren
Founder at ARGENX SE
Net worth: 34 M $ as of 2024-04-29
Network origin in Tim van Hauwermeiren first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
34
| Public Company | Pharmaceuticals: Other | 34 |
| Public Company | Biotechnology | 21 | |
| Public Company | Biotechnology | 19 | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Tim van Hauwermeiren via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| MIRATI THERAPEUTICS | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Director/Board Member President | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Founder Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| Katholieke Universiteit Leuven | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Masters Business Admin Doctorate Degree Graduate Degree Undergraduate Degree | |
| Ghent University | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing Compliance Officer | |
| KARA THER | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member President | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Undergraduate Degree Graduate Degree Graduate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree Graduate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| AMGEN INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Chairman | |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer Chief Operating Officer | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
Seragon Pharmaceuticals, Inc.
 Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Founder Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| TURG POIN | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Chief Executive Officer | |
| METACRINE, INC. | Biotechnology | Founder Chief Executive Officer Chief Operating Officer | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Graduate Degree | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| APELLIS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Pennsylvania Medical Center | College/University | Graduate Degree Doctorate Degree | |
| McGill University | College/University | Doctorate Degree Doctorate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree Corporate Officer/Principal | |
| OLEMA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Princeton University | College/University | Doctorate Degree Corporate Officer/Principal | |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Harvard Law School | College/University | Graduate Degree Graduate Degree | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member | |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Tibotec Virco NV
 Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Human Resources Officer | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Director of Finance/CFO Corporate Officer/Principal | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chairman | |
| ORIC PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Chief Executive Officer Chairman |
Statistics
International
| United States | 37 |
| Belgium | 8 |
| France | 3 |
| Spain | 3 |
| Netherlands | 2 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 14 |
| Finance | 6 |
| Commercial Services | 3 |
| Government | 2 |
Operational
| Director/Board Member | 462 |
| Corporate Officer/Principal | 182 |
| Independent Dir/Board Member | 137 |
| Chairman | 59 |
| Undergraduate Degree | 56 |
Most connected contacts
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| Richard Heyman | 33 |
| Bruno Montanari | 30 |
| Joseph deBethizy | 29 |
| Maha Katabi | 28 |
| Anthony Adam Rosenberg | 23 |
| Prabhavathi Fernandes | 23 |
| John Paul de Koning | 21 |
| Harrold van Barlingen | 20 |
| Peter K. M. Verhaeghe | 19 |
| Ann Rhoads | 19 |
| Aaron Davis | 19 |
| Aaron Kantoff | 19 |
| Aaron Royston | 19 |
| Pamela Klein | 19 |
- Stock Market
- Insiders
- Tim van Hauwermeiren
- Company connections